About Us

Ironshore Pharmaceuticals & Development, Inc. is a pharmaceutical company whose mission is to develop innovative, patient-centric treatment options, utilizing the proprietary DELEXIS® technology to improve the lives of patients and caregivers.

What We Do

Based in Grand Cayman, Ironshore Pharmaceuticals & Development, Inc. is responsible for managing all intellectual property, and directing all research, development and manufacturing activities for its drug candidates. Ironshore Pharmaceuticals & Development, Inc. is a wholly owned subsidiary of Toronto-based Highland Therapeutics Inc.

Ironshore Pharmaceuticals & Development, Inc.

Controlled Release

10 Market Street, Suite 715
Camana Bay, KY1-9006
Cayman Islands


David Lickrish
Chief Executive Officer

Nelson Isabel
Chief Financial Officer

Dr. Bev Incledon
Executive Vice President, Research & Development

Fiona McDougall
Senior Vice President, Operations

David Lickrish

David Lickrish is the co-inventor, founding shareholder and Chief Executive Officer of Ironshore Pharmaceuticals & Development, Inc.

Under his leadership, Ironshore has grown from a start-up company, founded in the midst of the financial crisis, to an international pharmaceutical company with a proprietary drug-delivery technology and two late-stage drugs under development.

Mr. Lickrish studied Microbiology and Finance at the University of Guelph in Canada. He graduated with Honors and received his Bachelor of Commerce in International Economics and Finance. Mr. Lickrish has been a CFA Charter holder since 2001 and has worked internationally covering the Global Pharmaceutical Industry as Senior Vice President of Equity Research.

Nelson Isabel

Nelson Isabel serves as the Company's Chief Financial Officer.

Prior to joining Ironshore, Mr. Isabel spent seven years at Biovail Corporation (now Bausch Health), Canada's largest publicly traded pharmaceutical company, where he served on its Finance Leadership Team and was responsible for all investor relations and corporate communication activities. Prior to Biovail, Mr. Isabel was an equity research analyst covering the Canadian healthcare industry with CIBC World Markets and with Desjardins Securities.

Mr. Isabel has a B.Sc. in Experimental Animal Physiology and a Master of Business Administration from the Schulich School of Business in Toronto. He has been a CFA Charter holder since 2002.

Dr. Bev Incledon

Dr. Incledon serves as the Company's Executive Vice President, Research & Development. Dr. Incledon has over 22 years of pharmaceutical industry experience encompassing drug discovery, product development, pre-approval inspections, development quality, project management, method/technology transfer, process improvement, manufacturing troubleshooting, new development facility start-up, and research on novel drug delivery technology.

Dr. Incledon was a Post-Doctoral Fellow at Cornell University, conducting his research in mathematical modeling of oxidative refolding of ribonuclease and the determination of refolding pathways in the presence of protein disulfide isomerase. He obtained his PhD degree in Biophysics and Bachelor of Science (Honors) in Applied Biochemistry with a Minor in Biomedical Technology from the University of Guelph with research focused on purification of a multi-subunit protein complex; characterization of subunit assembly and inhibition kinetics; identification of structural and kinetic differences responsible for resistance development and determination of subcellular localization of isozymes.

Fiona McDougall

Fiona McDougall is the Senior Vice President, Operations at Ironshore Pharmaceuticals & Development, Inc. Ms. McDougall has more than seventeen years of executive experience in strategic planning, business operations and project management in the health care and pharmaceuticals industries. Prior to joining Ironshore, Fiona held CEO and VP roles at health care consulting firms providing strategy and operations consulting services, advising clients on operational efficiency and delivering meaningful results for patients and stakeholders. Ms. McDougall has an Honors Bachelor degree from the University of Western Ontario and a Master of Business Administration degree from the Schulich School of Business in Toronto.